Development of Oral ATAC Degraders for Extracellular Proteins
- Harnessing natural cellular degradation machinery to eliminate pathogenic extracellular proteins ATACs (ASGPR-Targeting Chimeras)
- Discussing Avilar’s proprietary ASGPR ligands deliver superior affinity and optimized ADME properties, enabling differentiated product profiles. Also detailing from concept to candidate: Avilar’s systematic approach to developing oral ATACs
- Sharing ASGPR ligand optimization for continued improvement in oral bioavailability
- Achieving high oral bioavailability with multiple prototype ATACs targeting diverse proteins, including for Avilar’s cardiometabolic program